Evidence for the HIV-1 phenotype switch as a causal factor in acquired immunodeficiency

Svetlana Glushakova, Jean-Charles B. Grivel, Wendy Fitzgerald, Andrew Sylwester, Joshua Zimmerberg, Leonid B. Margolis

Research output: Contribution to journalArticle

99 Citations (Scopus)

Abstract

Both cellular and humoral immunodeficiency develop in vivo after prolonged infection with HIV-1, but the mechanisms are unclear. Initial infection with HIV-1 is transmitted by macrophage (M)-tropic/non-syncytia- inducing (NSI) viruses, which hyperactivate the immune system, and, in one view, cause immunodeficiency by 'exhaustion' of lymphoid tissue. An alternative hypothesis is that immunodeficiency is caused by the replacement of M-tropic viruses by T cell (T)-tropic/syncytia-inducing (SI) viruses, which are known to be highly cytopathic in vitro and emerge late in infected individuals around the time of transition to AIDS (refs. 1, 7-9). To test these two possibilities, we have developed an ex vivo model of humoral immunity to recall antigens using human lymphoid tissue. This tissue supports productive infection with both M- and T-tropic HIV-1 isolates when cultured ex vivo. We found that specific immune responses were enhanced by productive infection of the tissue with M-tropic/NSI HIV-1 isolates, but were blocked by T-tropic/SI HIV-1 isolates. The mechanism involves specific irreversible effect on B-cell activity. Our results support the hypothesis that the phenotype switch to T-tropic viruses is a key determinant of acquired humoral immunodeficiency in patients infected with HIV.

Original languageEnglish
Pages (from-to)346-349
Number of pages4
JournalNature Medicine
Volume4
Issue number3
DOIs
Publication statusPublished - 1998
Externally publishedYes

Fingerprint

Tropics
HIV-1
Switches
Phenotype
Viruses
Lymphoid Tissue
Giant Cells
Infection
Tissue
Humoral Immunity
Immune System
T-cells
Macrophages
Immune system
Acquired Immunodeficiency Syndrome
B-Lymphocytes
HIV
T-Lymphocytes
Antigens
Cells

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Glushakova, S., Grivel, J-C. B., Fitzgerald, W., Sylwester, A., Zimmerberg, J., & Margolis, L. B. (1998). Evidence for the HIV-1 phenotype switch as a causal factor in acquired immunodeficiency. Nature Medicine, 4(3), 346-349. https://doi.org/10.1038/nm0398-346

Evidence for the HIV-1 phenotype switch as a causal factor in acquired immunodeficiency. / Glushakova, Svetlana; Grivel, Jean-Charles B.; Fitzgerald, Wendy; Sylwester, Andrew; Zimmerberg, Joshua; Margolis, Leonid B.

In: Nature Medicine, Vol. 4, No. 3, 1998, p. 346-349.

Research output: Contribution to journalArticle

Glushakova, S, Grivel, J-CB, Fitzgerald, W, Sylwester, A, Zimmerberg, J & Margolis, LB 1998, 'Evidence for the HIV-1 phenotype switch as a causal factor in acquired immunodeficiency', Nature Medicine, vol. 4, no. 3, pp. 346-349. https://doi.org/10.1038/nm0398-346
Glushakova, Svetlana ; Grivel, Jean-Charles B. ; Fitzgerald, Wendy ; Sylwester, Andrew ; Zimmerberg, Joshua ; Margolis, Leonid B. / Evidence for the HIV-1 phenotype switch as a causal factor in acquired immunodeficiency. In: Nature Medicine. 1998 ; Vol. 4, No. 3. pp. 346-349.
@article{ad207fc62ae34e26ba708c8b3b3058c5,
title = "Evidence for the HIV-1 phenotype switch as a causal factor in acquired immunodeficiency",
abstract = "Both cellular and humoral immunodeficiency develop in vivo after prolonged infection with HIV-1, but the mechanisms are unclear. Initial infection with HIV-1 is transmitted by macrophage (M)-tropic/non-syncytia- inducing (NSI) viruses, which hyperactivate the immune system, and, in one view, cause immunodeficiency by 'exhaustion' of lymphoid tissue. An alternative hypothesis is that immunodeficiency is caused by the replacement of M-tropic viruses by T cell (T)-tropic/syncytia-inducing (SI) viruses, which are known to be highly cytopathic in vitro and emerge late in infected individuals around the time of transition to AIDS (refs. 1, 7-9). To test these two possibilities, we have developed an ex vivo model of humoral immunity to recall antigens using human lymphoid tissue. This tissue supports productive infection with both M- and T-tropic HIV-1 isolates when cultured ex vivo. We found that specific immune responses were enhanced by productive infection of the tissue with M-tropic/NSI HIV-1 isolates, but were blocked by T-tropic/SI HIV-1 isolates. The mechanism involves specific irreversible effect on B-cell activity. Our results support the hypothesis that the phenotype switch to T-tropic viruses is a key determinant of acquired humoral immunodeficiency in patients infected with HIV.",
author = "Svetlana Glushakova and Grivel, {Jean-Charles B.} and Wendy Fitzgerald and Andrew Sylwester and Joshua Zimmerberg and Margolis, {Leonid B.}",
year = "1998",
doi = "10.1038/nm0398-346",
language = "English",
volume = "4",
pages = "346--349",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Evidence for the HIV-1 phenotype switch as a causal factor in acquired immunodeficiency

AU - Glushakova, Svetlana

AU - Grivel, Jean-Charles B.

AU - Fitzgerald, Wendy

AU - Sylwester, Andrew

AU - Zimmerberg, Joshua

AU - Margolis, Leonid B.

PY - 1998

Y1 - 1998

N2 - Both cellular and humoral immunodeficiency develop in vivo after prolonged infection with HIV-1, but the mechanisms are unclear. Initial infection with HIV-1 is transmitted by macrophage (M)-tropic/non-syncytia- inducing (NSI) viruses, which hyperactivate the immune system, and, in one view, cause immunodeficiency by 'exhaustion' of lymphoid tissue. An alternative hypothesis is that immunodeficiency is caused by the replacement of M-tropic viruses by T cell (T)-tropic/syncytia-inducing (SI) viruses, which are known to be highly cytopathic in vitro and emerge late in infected individuals around the time of transition to AIDS (refs. 1, 7-9). To test these two possibilities, we have developed an ex vivo model of humoral immunity to recall antigens using human lymphoid tissue. This tissue supports productive infection with both M- and T-tropic HIV-1 isolates when cultured ex vivo. We found that specific immune responses were enhanced by productive infection of the tissue with M-tropic/NSI HIV-1 isolates, but were blocked by T-tropic/SI HIV-1 isolates. The mechanism involves specific irreversible effect on B-cell activity. Our results support the hypothesis that the phenotype switch to T-tropic viruses is a key determinant of acquired humoral immunodeficiency in patients infected with HIV.

AB - Both cellular and humoral immunodeficiency develop in vivo after prolonged infection with HIV-1, but the mechanisms are unclear. Initial infection with HIV-1 is transmitted by macrophage (M)-tropic/non-syncytia- inducing (NSI) viruses, which hyperactivate the immune system, and, in one view, cause immunodeficiency by 'exhaustion' of lymphoid tissue. An alternative hypothesis is that immunodeficiency is caused by the replacement of M-tropic viruses by T cell (T)-tropic/syncytia-inducing (SI) viruses, which are known to be highly cytopathic in vitro and emerge late in infected individuals around the time of transition to AIDS (refs. 1, 7-9). To test these two possibilities, we have developed an ex vivo model of humoral immunity to recall antigens using human lymphoid tissue. This tissue supports productive infection with both M- and T-tropic HIV-1 isolates when cultured ex vivo. We found that specific immune responses were enhanced by productive infection of the tissue with M-tropic/NSI HIV-1 isolates, but were blocked by T-tropic/SI HIV-1 isolates. The mechanism involves specific irreversible effect on B-cell activity. Our results support the hypothesis that the phenotype switch to T-tropic viruses is a key determinant of acquired humoral immunodeficiency in patients infected with HIV.

UR - http://www.scopus.com/inward/record.url?scp=0031953133&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031953133&partnerID=8YFLogxK

U2 - 10.1038/nm0398-346

DO - 10.1038/nm0398-346

M3 - Article

C2 - 9500611

AN - SCOPUS:0031953133

VL - 4

SP - 346

EP - 349

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 3

ER -